Lilly hopes to address immunology and pain indications with biotech’s LYTAC technology. Sunovion licenses European rights to Parkinson’s therapy Kynmobi to Bial.

Despite contraction in the number of funds and VC firms investing in life sciences, 2013 was a strong year for private investing in medtech, with private investors putting $2.54 million into 129 medical device deals, according to Informa’s Strategic Transactions. Looking at where investors placed their money revealed some emerging trends.

Recently incorporated Orthophoenix, which shares the same Dallas address as IPNav, a company that provides “full-service patent monetization,” is suing six device firms for infringement of the Medtronic kyphoplasty patents it recently acquired.

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors.